Share price of The Cooper Companies (COO - Free Report) rallied to a new 52-week high of $190.75 on Sep 15, eventually closing a tad lower at $189.90. This represents a strong year-to-date return of approximately 41.5%, better than the S&P 500’s 5% over the same time frame.
Currently, Cooper Companies carries a Zacks Rank #3 (Hold). The stock has a market cap of $9.04 billion and long-term expected earnings growth rate of 11.8%.
Growth Catalysts
A solid product pipeline is a major positive for the company in our view. Especially, the launch of Avaira Vitality in the U.S. buoys optimism as the product is expected to drive margins over the long haul. Additionally, the rollout of MyDay in Japan is a noteworthy development as it is expected to fortify the company’s market position.
Meanwhile, we note that each and every business segment of the company contributed toward the current growth trend. The CooperVision segment (CVI) of the company posted a stellar performance in the last-reported third quarter of 2016, raking in revenues of $409.9 million (up 6% at constant currency). Particularly, the Toric, Multifocal and Sphere lenses deserve special mention here. The CooperSurgical (CSI) unit of the company performed exceptionally well as well, enhancing the growth trajectory.
In this regard, Cooper Companies reported an impressive third quarter of 2016 with revenues of $514.7 million improving 6% year over year at constant currency. Notably, adjusted earnings of $2.30 per share beat the Zacks Consensus Estimate by 2 cents, up 16.8% on a year-over-year basis.
Estimate Revisions
The company’s current year estimate revision trend is also looking quite promising with 8 estimates moving higher over the past two months, compared to one downward revision. The consensus estimate trend has also seen a boost for this time frame, increasing by 3 cents to $8.41 per share.
Key Picks
Better-ranked stocks in the broad medical sector include Halyard Health Inc , INC Research Holdings Inc. (INCR - Free Report) and Lonza Group Limited (LZAGY - Free Report) . Notably, all the companies sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Share price of The Cooper Companies (COO - Free Report) rallied to a new 52-week high of $190.75 on Sep 15, eventually closing a tad lower at $189.90. This represents a strong year-to-date return of approximately 41.5%, better than the S&P 500’s 5% over the same time frame.
Currently, Cooper Companies carries a Zacks Rank #3 (Hold). The stock has a market cap of $9.04 billion and long-term expected earnings growth rate of 11.8%.
Growth Catalysts
A solid product pipeline is a major positive for the company in our view. Especially, the launch of Avaira Vitality in the U.S. buoys optimism as the product is expected to drive margins over the long haul. Additionally, the rollout of MyDay in Japan is a noteworthy development as it is expected to fortify the company’s market position.
Meanwhile, we note that each and every business segment of the company contributed toward the current growth trend. The CooperVision segment (CVI) of the company posted a stellar performance in the last-reported third quarter of 2016, raking in revenues of $409.9 million (up 6% at constant currency). Particularly, the Toric, Multifocal and Sphere lenses deserve special mention here. The CooperSurgical (CSI) unit of the company performed exceptionally well as well, enhancing the growth trajectory.
In this regard, Cooper Companies reported an impressive third quarter of 2016 with revenues of $514.7 million improving 6% year over year at constant currency. Notably, adjusted earnings of $2.30 per share beat the Zacks Consensus Estimate by 2 cents, up 16.8% on a year-over-year basis.
Estimate Revisions
The company’s current year estimate revision trend is also looking quite promising with 8 estimates moving higher over the past two months, compared to one downward revision. The consensus estimate trend has also seen a boost for this time frame, increasing by 3 cents to $8.41 per share.
Key Picks
Better-ranked stocks in the broad medical sector include Halyard Health Inc , INC Research Holdings Inc. (INCR - Free Report) and Lonza Group Limited (LZAGY - Free Report) . Notably, all the companies sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on COO - FREE
Get the latest research report on LZAGY - FREE
Get the latest research report on INCR - FREE